USA flag logo/image

An Official Website of the United States Government

DNA Aptamer Induction of Anthrax Germination

Award Information

Agency:
Department of Defense
Branch:
Army
Award ID:
62932
Program Year/Program:
2003 / SBIR
Agency Tracking Number:
A022-0519
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
OMNISITE BIODIAGNOSTICS, INC.
101 West Sixth Street Suite 200 Austin, TX 78701
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2003
Title: DNA Aptamer Induction of Anthrax Germination
Agency / Branch: DOD / ARMY
Contract: DAAD19-03-C-003
Award Amount: $69,995.00
 

Abstract:

OmniSite BioDiagnostics Inc. proposes to determine the feasibility of using DNA Aptamers to bind key germinant receptors on nonpathogenic Sterne strain anthrax spores to induce synchronous germination, hence leading to more effective antibiotic treatmentof inhalation anthrax. DNA Aptamers are short oligonucleotides that act like antibodies by binding any target against which they are raised with very high affinity and specificity. Aptamers are generated by a process called SELEX (Systematic Evolution ofLigands by EXponential enrichment) consisting of alternating iterations of affinity selection (from a random DNA library allowed to interact with the immobilized target), washing and PCR amplification of selected DNA sequences that bind the target. Dr.Bruno (proposed PI and CTO of OmniSite) is well versed and published in the area of Aptamer generation and assay development. In fact, Dr. Bruno made and published on the first anthrax spore binding DNA Aptamers (Bruno & Kiel, Biosensors & Bioelectronics1999). OmniSite proposes separation and characterization of inner and outer cortex proteins (by PAGE followed by Coomassie and silver staining) from anthrax spores with generation of aptamers to each identified protein. Then OmniSite will test theaptamers generated for their ability to enhance or inhibit spore germination by colony counts. This proposed project has several major scientific benefits in that, if successful, it may uncover previously unknown spore receptors that turn on germination and it will increase scientific understanding of the germination process. In a business sense,the project may lead to new therapeutic Aptamers capable of enhancing spore germination so that ciprofloxacin and other antibiotics can be more effective at killing the vegetative form of B. anthracis. In a broader sense too, technology gained byperformance of the project may lead to new Aptamer-based ways to kill or inhibit pathogenic bacteria.

Principal Investigator:

John G. Bruno
Chief Technical Officer
5124797732
bruno@spec.com

Business Contact:

Austin Sequeira
CEO
5124797732
sequeira@spec.com
Small Business Information at Submission:

OMNISITE BIODIAGNOSTICS, INC.
101 West Sixth Street, Suite 200 Austin, TX 78701

EIN/Tax ID: 742975605
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No